Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 4/20 | 0.38 |
| ▸ | F2R | P25116 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29158576 | 1.00 | USP30 (0.39) | USP30SMYD3F2RHCRTR2NR1H2 | |
| SCHEMBL29158578 | 1.00 | USP30 (0.39) | USP30SMYD3F2RHCRTR2NR1H2 | |
| SCHEMBL29470220 | 1.00 | USP30 (0.39) | USP30SMYD3F2RHCRTR2NR1H2 | |
| SCHEMBL29770996 | 0.90 | USP30 (0.39) | USP30F2RNR1H2KDM4DAR | |
| SCHEMBL23085670 | 0.90 | USP30 (0.39) | USP30F2RNR1H2KDM4DAR | |
| SCHEMBL29158591 | 0.90 | USP30 (0.39) | USP30F2RNR1H2KDM4DAR | |
| SCHEMBL29158595 | 0.90 | USP30 (0.39) | USP30F2RNR1H2KDM4DAR | |
| SCHEMBL23085659 | 0.89 | USP30 (0.39) | USP30F2RNR1H2KDM4D | |
| SCHEMBL29770913 | 0.89 | USP30 (0.39) | USP30F2RNR1H2KDM4D | |
| SCHEMBL29158658 | 0.89 | USP30 (0.39) | USP30F2RNR1H2KDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4025573-B9 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2024-11-20 | — | — | EP | disclosed |
| EP-4025573-B1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2024-07-24 | — | — | EP | disclosed |
| US-20220315572-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| EP-4025573-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2022-07-13 | — | — | EP | disclosed |
| CN-114341133-A | Substituted cyanopyrrolidines with USP30 inhibitor activity | 特殊治疗有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021043870-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2021-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315572-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP36, USP28 | USP30 1/4885SMYD3 1243/4885F2R 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.